Emcure Pharmaceuticals has announced that its Board of Directors has approved a proposal to acquire the remaining 20.42% minority stake in its subsidiary, Zuventus Healthcare Ltd. The acquisition will result in Zuventus becoming a wholly owned subsidiary of Emcure.
The company stated that it has entered into an agreement with Zuventus’ minority shareholders to purchase their stake, with the transaction expected to be completed in the second quarter of FY 2026.
Emcure emphasized that the Indian pharmaceutical market remains a key strategic priority. By consolidating its ownership in Zuventus, the company aims to achieve full financial integration and unlock operational synergies, thereby driving long-term value creation.
“The acquisition is in line with our focus on strengthening our domestic business and ensuring alignment across all operational verticals,” the company noted in its statement.
Zuventus Healthcare is a significant player in the Indian pharmaceutical landscape, and this move is seen as a step toward further reinforcing Emcure’s position in the market.
